Engineering Antibody Evolution: Germline‐Targeting HIV Vaccines Reach a Turning Point
This commentary examines three recent Nature studies demonstrating a conceptual shift in HIV vaccine design, demonstrating how germline-targeting HIV vaccines can progress beyond expanding rare broad neutralizing antibody (bnAb) precursors to deliberately guiding their affinity maturation into bnAbs in non-human primates.
Authors
- Deborah Lilly Burnett (ORCID: https://orcid.org/0000-0002-5642-3315)
- Rowena Anne Bull (ORCID: https://orcid.org/0000-0002-9844-3744)
Institutions
- Garvan Institute of Medical Research (AU)
- UNSW Sydney (AU)
- Kirby Institute (AU)
Publication Details
- Journal
- Immunology and Cell Biology
- Published
- 2026-10-06
- DOI
- https://doi.org/10.1111/imcb.70169
- Primary Topic
- HIV Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00